ENTRY       D12379                      Drug
NAME        Galegenimab (USAN/INN)
FORMULA     C2066H3194N550O673S12
EXACT_MASS  46860.9262
MOL_WEIGHT  46889.5278
SEQUENCE    (Heavy chain)
            EVQLVQSGAE VKKPGASVKV SCKASGYKFT DSEMHWVRQA PGQGLEWIGG VDPETEGAAY
            NQKFKGRATI TRDTSTSTAY LELSSLRSED TAVYYCTRGY DYDYALDYWG QGTLVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCD
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCRASSSVE FIHWYQQKPG KAPKPLISAT SNLASGVPSR
            FSGSGSGTDF TLTISSLQPE DFATYYCQQW SSAPWTFGQG TKVEIKRTVA APSVFIFPPS
            DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
            SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
            (Disulfide bridge: H22-H96, H146-H202, H222-L213, L23-L87, L133-L193)
  TYPE      Peptide
EFFICACY    Angiogenesis inhibitor, Anti-HtrA serine peptidase 1 antibody
  TYPE      Monoclonal antibody
COMMENT     Treatment of geographic atrophy
TARGET      HTRA1 [HSA:5654] [KO:K08784]
BRITE       Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Serine peptidases
                HTRA1
                 D12379  Galegenimab (USAN/INN)
DBLINKS     CAS: 2403683-24-7
///
